Showing 4781-4790 of 5646 results for "".
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- Fewer Side Effects Helped Spur Pfizer, BioNTech to Advance BNT162b2 Over Earlier COVID-19 Vaccine Candidatehttps://modernod.com/news/fewer-side-effects-helped-spur-pfizer-biontech-to-advance-bnt162b2-over-earlier-covid-19-vaccine-candidate/2478189/Pfizer and BioNTech released more details about why they recently selected their experimental coronavirus vaccine BNT162b2 over another candidate to advance into late-stage testing. According to a paper available on the medRxiv preprint server presenting additional phase 1 data from an ongoing US
- Kubota Vision Receives Orphan Products Clinical Trial Grant for Stargardt Disease Treatment Candidatehttps://modernod.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/Kubota Vision announced that the FDA Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease. Orphan product clinical trial grants support well-controlled studies that will eithe
- WSJ: Troubled COVID-19 Data System Returning to CDChttps://modernod.com/news/wsj-troubled-covid-19-data-system-returning-to-cdc/2478184/The U.S. Department of Health and Human Services is reversing course on a change to the way hospitals report critical information on the coronavirus pandemic to the government, returning the responsibility for data collection to the Centers for Disease Control and Prevention, according to a W
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo
- BVI Launches IPure Aspheric Monofocal IOL in the UShttps://modernod.com/news/bvi-launches-ipure-aspheric-monofocal-iol-in-the-us/2478172/BVI has entered the US IOL market with the launch of the IPure preloaded aspheric monofocal IOL. BVI says the IPure is the first and only preloaded aspheric monofocal IOL available in both a 1-piece and 3-piece design. IPure’s patented aspheric optic design provides high contract, hi
- How COVID-19 is Shaking Up Medical Education—For Goodhttps://modernod.com/news/how-covid-19-is-shaking-up-medical-education-for-good/2478168/With COVID-19 shows no signs of letting up soon, leaders at medical schools are adapting their plans for education in the fall to meet the new demands of the pandemic, according to a FierceHealthcare report. That means going digital in an unprecedented way—both in terms of classe
- Avellino Hits 1-Million Genetic Test Milestonehttps://modernod.com/news/avellino-hits-1-million-genetic-test-milestone/2478164/Avellino announced that the company has performed over 1-million genetic and molecular diagnostic tests. This milestone includes over 821,000 universal tests for TGFBI corneal dystrophy, over 180,000 AvellinoSARS-CoV-2/COVID-19 (AvellinoCoV2) tests since March 2020, and the November 2019 launch o
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont